EPHA1 Antibody

What is EphA1 and what cellular locations can it be found in?

EphA1 is a receptor tyrosine kinase belonging to the Eph receptor family, involved in cell signaling and regulation of cell adhesion and migration. While primarily characterized as a transmembrane protein, research has revealed more complex localization patterns. EphA1 is commonly found in the cell membrane as a single-pass type I membrane protein, but it has also been detected in the nucleus of certain cell types . This nuclear localization is dynamic and changes throughout the cell cycle. During prophase, EphA1 colocalizes with DNA, indicating nuclear restriction, but as cells progress toward metaphase, EphA1 becomes diffusely distributed throughout the cell and maintains this diffuse localization through mitosis and cytokinesis .

This dual localization pattern suggests that EphA1 may have distinct functions depending on its cellular compartmentalization, potentially influencing both membrane-associated signaling and nuclear processes. The nuclear localization of EphA1 remains an area of ongoing research to determine its functional significance.

What is the molecular weight of EphA1 and why might it vary in western blot analysis?

Full-length EphA1 can be detected at approximately 130 kDa in some cell lines , but researchers often observe additional bands at around 60 kDa using antibodies directed against the C-terminal region . This 60 kDa fragment represents a proteolytic product of EphA1. Additionally, metalloproteases can cleave EphA1 in the FN2 domain and near the transmembrane helix, generating ectodomain fragments of approximately 70 kDa and 55 kDa that can be detected in the culture medium .

The observed variability in molecular weight across different studies may result from:

• Cell type-specific post-translational modifications

• Differential proteolytic processing

• Variations in SDS-PAGE conditions

• Antibody specificity (N-terminal vs. C-terminal epitopes)

Researchers should always validate the specificity of their antibody using appropriate controls, such as cell lines known to express or not express EphA1, and blocking peptides when available.

What are the most common applications for EPHA1 antibodies in research?

EPHA1 antibodies are versatile tools employed in multiple experimental applications:

When designing experiments using EPHA1 antibodies, researchers should consider:

• Different antibodies may recognize distinct epitopes (extracellular vs. intracellular domains)

• Fixation methods can affect epitope accessibility

• Positive controls should be included (tissues/cells known to express EphA1)

• Blocking peptides can help confirm specificity

How can I distinguish between full-length EPHA1 and its proteolytic fragments in my experiments?

Distinguishing between full-length EPHA1 and its proteolytic fragments requires strategic antibody selection and experimental design:

• Epitope-specific antibodies: Use antibodies targeting different domains of EPHA1:

  • Extracellular domain antibodies (like AER-011) recognize the N-terminal region and detect full-length receptor and secreted ectodomain fragments

  • SAM domain antibodies detect the C-terminal fragments (~60 kDa) and full-length receptor

• Subcellular fractionation: Isolate nuclear, cytoplasmic, and membrane fractions before western blotting to determine the subcellular localization of different EPHA1 forms

• Protease inhibitors: Include metalloprotease inhibitors like GM6001 in your experiments. Long-term (2 days) treatment with GM6001 can significantly reduce ectodomain shedding, allowing better detection of full-length EPHA1

• Molecular weight analysis: Full-length EPHA1 appears at ~100-130 kDa, while the main C-terminal fragment is ~60 kDa. Additional ectodomain fragments of ~70 kDa and ~55 kDa may be detected in culture media

• Validation controls:

  • Use cells expressing EPHA1 wild-type versus mutants with altered proteolytic processing (like P460L)

  • Include specific blocking peptides to confirm antibody specificity

Research has shown that EPHA1 undergoes cleavage by metalloproteases, particularly MMPs (including MMP14, MMP7, and MMP2), generating fragment patterns that may have distinct physiological significance . The 60 kDa C-terminal fragment associates strongly with full-length EPHA1, requiring 1% SDS treatment to disrupt this interaction, suggesting functional relevance of these fragment associations .

What methodological approaches can be used to study EPHA1 phosphorylation in experimental systems?

Studying EPHA1 phosphorylation requires specialized techniques that can capture this dynamic post-translational modification:

• Phospho-specific antibodies:

  • Antibodies targeting specific phosphorylation sites like S906 can detect activated EPHA1

  • These antibodies should be validated using phosphorylation-deficient mutants (e.g., S906A)

• Immunoprecipitation followed by phospho-detection:

  • Immunoprecipitate EPHA1 using total EPHA1 antibodies

  • Probe blots with anti-phosphotyrosine antibodies (e.g., pY99) to detect general tyrosine phosphorylation

  • Use site-specific phospho-antibodies to detect particular phosphorylation events

• Kinase assays:

  • In vitro kinase assays using purified EPHA1 kinase domain

  • Detection of phosphorylation can be done using radiolabeled ATP or phospho-specific antibodies

• Stimulus-response experiments:

  • Treatment with ephrin ligands induces EPHA1 Y781 phosphorylation in wild-type receptors

  • Compare phosphorylation between wild-type and mutant receptors (e.g., P460L shows reduced phosphorylation)

  • Optimize stimulus duration and concentration

• Downstream signaling markers:

  • Monitor phosphorylation of MAPK/ERK pathway components (p-p44/42 MAPK T202/Y204)

  • Compare activation patterns between wild-type and mutant forms

A significant methodological advance involves the development of optogenetic EphA1 constructs that allow precise temporal control of receptor activation. These constructs (such as PMa-EphA1Cry2) can be transfected into cells like HEK293T and activated with blue light exposure, allowing real-time monitoring of receptor clustering and signaling .

For distinguishing between canonical and non-canonical signaling, researchers should note that EphA1 phosphorylation on S906 appears to occur at the plasma membrane, similar to S897 phosphorylation in EphA2, suggesting a non-canonical signaling mechanism .

How does the P460L variant of EPHA1 affect its function, and what methods can be used to study this variant?

The P460L variant of EPHA1 has been identified as a risk factor for late-onset Alzheimer's disease (LOAD) and exhibits several functional alterations compared to wild-type EPHA1:

To study the P460L variant, researchers can employ several methodological approaches:

• Isogenic cell models: Generate HEK cells expressing either wild-type EphA1 or P460L variant for direct comparison

• Proteolytic processing analysis:

  • Compare wild-type and P460L variant expression and processing using antibodies against different domains

  • Use proteasome inhibitors (e.g., MG132) to prevent degradation of P460L fragments

• Functional assays:

  • Brain endothelial cell barrier function (transendothelial electrical resistance)

  • T-cell recruitment assays to assess reverse signaling effects

  • Receptor clustering and activation with soluble ligands

• Biochemical characterization:

  • Pulse-chase experiments to track protein stability

  • Co-immunoprecipitation to assess binding partner interactions

  • Surface plasmon resonance to measure binding affinities

The P460L mutation affects not only forward signaling through reduced membrane expression and phosphorylation but also impacts reverse signaling to brain endothelial cells, potentially contributing to altered blood-brain barrier function in LOAD patients . This highlights the importance of studying both signaling directions when investigating EPHA1 variants.

What are the considerations when selecting EPHA1 antibodies for studying its expression in cancer tissues?

Selecting appropriate EPHA1 antibodies for cancer tissue studies requires careful consideration of multiple factors:

• Histological characteristics of the cancer tissue:

  • For melanin-rich tissues like uveal melanoma, use red chromogen visualization kits that enable detection in melanin-containing samples

  • Consider tissue-specific background and optimize blocking steps

• Expression pattern evaluation:

  • EPHA1 shows both cytoplasmic and occasionally membranous staining patterns in cancer tissues

  • Use a scoring system that accounts for both percentage of positive cells and reaction intensity

  • Consider the "quickscore" method (sum of percentage score [0-3] and intensity score [0-3])

• Antibody validation requirements:

  • Use positive controls (e.g., hepatocellular carcinoma and breast cancer tissues are recommended for many EPHA1 antibodies)

  • Include negative controls (antibody pre-absorption with specific blocking peptides)

• Quantification approaches:

  • Establish clear scoring criteria (example from uveal melanoma study):

• Prognostic correlation analysis:

  • EPHA1 expression patterns vary by cancer type and may have opposite prognostic implications

  • In uveal melanoma, high EPHA1 expression associates with favorable factors (smaller tumor size, lower mitotic activity, less frequent chromosome 3 loss)

  • In colorectal cancer, low EPHA1 expression correlates with shorter survival

When publishing results, clearly report the antibody clone, dilution, incubation conditions, detection method, and scoring system. Be aware that antibody performance may vary between fresh frozen and formalin-fixed paraffin-embedded tissues. For research involving multiple Eph receptors (like EphA1, EphA5, and EphA7), ensure antibody specificity to avoid cross-reactivity with other family members.

What are the best practices for validating the specificity of EPHA1 antibodies?

Validating EPHA1 antibody specificity is critical for ensuring reliable experimental results. Here are comprehensive validation approaches:

• Multiple antibody validation:

  • Use antibodies targeting different epitopes of EPHA1 (e.g., extracellular domain, kinase domain, SAM domain)

  • Compare staining/detection patterns between different antibodies

  • If patterns match across antibodies from different vendors/clones, specificity is supported

• Blocking peptide controls:

  • Pre-incubate antibody with excess specific blocking peptide (e.g., EphA1 extracellular blocking peptide for AER-011)

  • Run parallel experiments with blocked and unblocked antibody

  • Loss of signal in blocked samples confirms specificity

• Genetic validation:

  • Use EPHA1 knockout cell lines or CRISPR/Cas9-mediated EPHA1 deletion

  • Compare antibody reactivity in wild-type versus knockout samples

  • Signal should be absent in knockout samples

• Recombinant protein controls:

  • Test antibody against purified recombinant EPHA1 protein

  • Include related Eph family proteins to assess cross-reactivity

  • Ideally, antibody should react only with EPHA1 and not with other Eph receptors

• siRNA knockdown:

  • Transfect cells with EPHA1-specific siRNA

  • Confirm knockdown efficiency by qRT-PCR

  • Reduction in antibody signal proportional to knockdown confirms specificity

• Overexpression systems:

  • Transfect cells with EPHA1 expression constructs

  • Increased signal in transfected versus non-transfected cells supports specificity

In practice, researchers have validated EPHA1 antibodies through methods such as cross-absorption on columns with closely related proteins (e.g., EPHA2) to eliminate antibodies recognizing conserved epitopes . For phospho-specific antibodies like those targeting phosphorylated S906, validation includes demonstrating reactivity with wild-type EPHA1 but not with the S906A mutant .

How should EPHA1 antibodies be optimized for different experimental applications?

Optimizing EPHA1 antibodies for different applications requires tailored approaches:

Western Blot Optimization:

• Sample preparation: Test different lysis buffers (TX-100, RIPA, SDS) as buffer composition affects detection of membrane-associated EphA1 versus cleaved fragments

• Protein loading: 20-50 μg total protein recommended; higher amounts may be needed for endogenous detection

• Dilution range: Start with 1:200-1:500 for detecting endogenous EPHA1; can use up to 1:2000 for overexpressed protein

• Blocking: 5% BSA in TBST generally preferred over milk for phospho-epitopes

• Detection system: Enhanced chemiluminescence with longer exposure times may be needed for endogenous EPHA1

Immunohistochemistry Optimization:

• Antigen retrieval: Critical for formalin-fixed tissues; test both citrate (pH 6.0) and EDTA (pH 9.0) buffers

• Dilution: Start with 1:300 and optimize based on signal-to-noise ratio

• Detection system: For melanin-rich tissues, use red chromogen visualization instead of DAB

• Controls: Include known positive tissues (hepatocellular carcinoma, breast cancer) as recommended by manufacturers

Immunocytochemistry/Immunofluorescence:

• Fixation: Compare 4% paraformaldehyde (10 min) versus methanol (-20°C, 10 min)

• Permeabilization: 0.1-0.2% Triton X-100 (5-10 min) for intracellular epitopes

• Antibody concentration: 1:25-1:100 for cell lines; higher concentrations (5-10 μg/mL) may be needed

• Counterstains: DAPI for nuclei; consider phalloidin for F-actin to visualize cell boundaries

Flow Cytometry:

• Cell preparation: Gentle dissociation methods to preserve membrane proteins

• Antibody amount: ~2.5 μg per sample for detection of surface EphA1

• Indirect staining: Use fluorophore-conjugated secondary antibodies with minimal spectral overlap

• Live cell staining: For surface detection, omit permeabilization and use antibodies against extracellular domains

For all applications, titration experiments are essential to determine optimal antibody concentration. Background signal can be reduced by extending wash steps and optimizing blocking conditions (BSA, normal serum, commercial blockers). When possible, include both positive and negative controls in each experiment.

What are the most common pitfalls when using EPHA1 antibodies, and how can they be avoided?

Researchers frequently encounter several challenges when working with EPHA1 antibodies. Here are the common pitfalls and strategies to avoid them:

• Multiple band detection and misinterpretation:

  • Pitfall: Confusion about which band represents full-length EPHA1 versus proteolytic fragments

  • Solution: Use molecular weight markers carefully; full-length EPHA1 is ~100-130 kDa, C-terminal fragment ~60 kDa

  • Mitigation: Include positive controls with known EPHA1 expression patterns; use epitope-specific antibodies

• False-negative results in tissues with high EPHA1 cleavage:

  • Pitfall: Low detection of full-length EPHA1 in tissues with active metalloprotease activity

  • Solution: Include metalloprotease inhibitors in tissue preparation; analyze both cell lysates and culture media

  • Mitigation: Use antibodies against both extracellular and intracellular domains

• Non-specific staining in immunohistochemistry:

  • Pitfall: Background staining misinterpreted as positive signal

  • Solution: Include blocking peptide controls; optimize antibody dilution and incubation time

  • Mitigation: Score staining intensity and percentage systematically; have multiple pathologists evaluate slides

• Inconsistent results between applications:

  • Pitfall: Antibody works for western blot but not immunohistochemistry

  • Solution: Different applications may require different antibodies/clones

  • Mitigation: Validate each antibody specifically for each application

• Cross-reactivity with other Eph receptors:

  • Pitfall: Signal attributed to EPHA1 actually comes from related Eph family members

  • Solution: Use antibodies validated for specificity; consider cross-absorption against related proteins

  • Mitigation: Compare results with mRNA expression data; use genetic knockdown controls

• Poor reproducibility in phosphorylation studies:

  • Pitfall: Inconsistent detection of phosphorylated EPHA1

  • Solution: Carefully control cell stimulation conditions; include phosphatase inhibitors in lysis buffers

  • Mitigation: Use phospho-specific antibodies validated with phosphorylation-deficient mutants

• Cell cycle-dependent localization variability:

  • Pitfall: Inconsistent localization patterns between experiments

  • Solution: Consider that EPHA1 localization changes through the cell cycle

  • Mitigation: Co-stain with cell cycle markers (e.g., phospho-histone H3) to correlate localization with cell cycle phase

• Variant-specific detection issues:

  • Pitfall: Antibodies may have different affinities for wild-type versus variant EPHA1 (e.g., P460L)

  • Solution: Use multiple antibodies targeting different epitopes

  • Mitigation: Include both wild-type and variant controls when studying disease-associated variants

By anticipating these common issues and implementing the suggested solutions, researchers can significantly improve the reliability and reproducibility of their EPHA1 antibody-based experiments.

How can EPHA1 antibodies be used to study its role in neurodegenerative diseases like Alzheimer's?

EPHA1 has emerged as a significant risk factor for late-onset Alzheimer's disease (LOAD), with variants like P460L affecting receptor function. Here are methodological approaches using EPHA1 antibodies to investigate its role in neurodegeneration:

• Blood-brain barrier (BBB) function studies:

  • Use antibodies against wild-type EPHA1 and P460L in brain endothelial cell models

  • Compare receptor localization and activation patterns

  • Measure barrier integrity using transendothelial electrical resistance while modulating EPHA1 activity

  • Assess T-cell recruitment across BBB models with varying EPHA1 expression

• Neuroinflammatory signaling detection:

  • Use phospho-specific antibodies to track EPHA1 activation in neuroinflammatory conditions

  • Co-stain with markers of microglial activation and astrogliosis

  • Compare phosphorylation patterns in control versus AD patient-derived samples

  • Correlate with inflammatory cytokine profiles

• EPHA1 cleaved fragment analysis in CSF:

  • Develop sensitive ELISA or multiplexed assays using antibodies against different EPHA1 domains

  • Quantify soluble EPHA1 fragments in cerebrospinal fluid from control subjects versus AD patients

  • Compare fragment patterns between wild-type and variant carriers (e.g., P460L)

  • Assess potential as biomarkers for disease progression

• Receptor-ligand interaction studies:

  • Use antibodies to detect EPHA1-ephrin binding in brain tissue sections

  • Employ proximity ligation assays to visualize interactions in situ

  • Compare interaction patterns in normal versus pathological tissues

  • Assess effects of blocking antibodies on downstream signaling

• Therapeutic targeting approaches:

  • Develop and test therapeutic antibodies that could modulate EPHA1 signaling

  • Use existing antibodies to track on-target engagement

  • Monitor effects on BBB integrity, neuroinflammation, and amyloid clearance

  • Compare efficacy in wild-type versus variant models

Recent research indicates that EPHA1-dependent reverse signaling controls T-cell recruitment by brain endothelial cells and remodels endothelial cell contacts . The P460L variant shows reduced membrane expression, reduced ligand responses, and fails to effectively signal to brain endothelial cells, potentially contributing to BBB dysfunction in LOAD . These findings suggest that modulating EPHA1 activity might represent a novel therapeutic approach for addressing neuroinflammatory aspects of AD pathogenesis.

What are the latest advances in developing EPHA1 antibodies for research and therapeutic applications?

Recent advances in EPHA1 antibody development have expanded both research capabilities and therapeutic potential:

• Domain-specific antibodies for mechanistic studies:

  • SAM domain antibodies: Developed through affinity purification against His-tagged EPHA1 kinase-SAM linker and SAM domain proteins, with cross-absorption against related proteins like EPHA2

  • Phospho-specific antibodies: Targeting phosphorylated residues (e.g., S906) using phosphopeptide immunization and dual-step affinity purification

  • Extracellular domain antibodies: Targeting specific epitopes (amino acids 457-471) for cell surface detection

• Antibody-based imaging approaches:

  • Fluorescently labeled antibodies for non-invasive imaging of EPHA1 expression

  • Development of antibody fragments (Fab, scFv) with improved tissue penetration

  • Multiplexed imaging systems allowing simultaneous detection of multiple Eph receptors

• Therapeutic development strategies:

  • Blocking antibodies targeting EPHA1-ephrin interactions

  • Antibodies that modulate receptor cleavage or activation state

  • Bispecific antibodies linking EPHA1 with immune effector cells

  • Antibody-drug conjugates for targeted delivery to EPHA1-expressing cells

• Engineered antibody systems:

  • Optogenetic approaches: Development of light-activated EPHA1 constructs (e.g., PMa-EphA1Cry2) enabling precise temporal control of receptor activation

  • Stimulus-responsive antibodies with conditional binding properties

  • PROTAC (Proteolysis Targeting Chimera) linked antibodies for induced protein degradation

• Single-cell applications:

  • Antibodies optimized for flow cytometry and cell sorting based on EPHA1 expression

  • Single-cell imaging compatible formulations with minimal background

  • Antibodies for mass cytometry (CyTOF) applications

The development of these advanced antibody tools facilitates innovative research approaches for understanding EPHA1 biology. For example, the optogenetic regulation of EPHA1 using Cry2olig-mCherry fusion constructs allows researchers to precisely control and visualize receptor clustering and activation in real-time using blue light exposure . This technique has revealed important insights about membrane localization dynamics and downstream signaling events.

For therapeutic applications, researchers are particularly interested in modulating EPHA1's role in maintaining blood-brain barrier integrity and regulating neuroinflammation, especially given its genetic association with Alzheimer's disease risk .

How should researchers interpret contradictory findings about EPHA1 expression and function across different studies?

Contradictory findings regarding EPHA1 expression and function are common in the literature and require careful interpretation considering several methodological and biological factors:

• Antibody-related technical considerations:

  • Different antibodies target distinct epitopes, potentially detecting different EPHA1 forms

  • Variations in antibody sensitivity and specificity across studies

  • Methodological differences in tissue preparation, fixation, and antigen retrieval

  • Solution: Cross-validate findings using multiple antibodies targeting different domains

• Context-dependent biology:

  • EPHA1 exhibits tissue-specific and cell cycle-dependent localization patterns

  • Proteolytic processing varies across tissue/cell types and disease states

  • Post-translational modifications affect antibody recognition

  • Solution: Clearly define experimental context and cell/tissue type when reporting results

• Disease-specific expression patterns:

  • EPHA1 has opposite prognostic implications in different cancers:

    • In uveal melanoma: High expression correlates with favorable prognostic factors

    • In colorectal cancer: Low expression associates with shorter survival

    • In pancreatic adenocarcinoma: High expression correlates with shorter survival

  • Solution: Consider disease-specific microenvironmental factors and signaling networks

• Signaling complexity:

  • EPHA1 mediates both forward and reverse signaling

  • Variants like P460L differently affect these signaling modes

  • Receptor clustering and cleavage patterns influence functional outcomes

  • Solution: Assess multiple aspects of EPHA1 biology rather than focusing on expression alone

• Genetic variation influence:

  • Variants like P460L show reduced membrane expression and altered signaling

  • Population-specific genetic backgrounds may influence EPHA1 function

  • Solution: Consider genotype information when available; use isogenic models for direct comparisons

When interpreting EPHA1 studies, researchers should evaluate the quality of controls, antibody validation methods, and the biological context carefully. Comprehensive approaches that combine multiple detection methods (protein, mRNA, functional assays) provide the most reliable insights into EPHA1 biology across different physiological and pathological states.